High levels of donor CCL2/MCP-1 predict graft-related complications and poor graft survival after kidney-pancreas transplantation

Am J Transplant. 2008 Jun;8(6):1303-11. doi: 10.1111/j.1600-6143.2008.02240.x. Epub 2008 Apr 29.

Abstract

In this study we analyzed the role of CCL2, a member of the chemokine family, in early graft damage. Using simultaneous kidney-pancreas transplantation (SPK) as a model, we showed that brain death significantly increases circulating CCL2 levels in humans. We found that in such situations, high donor CCL2 levels (measured before organ recovery and at the onset of cold preservation) correlate with increased postreperfusion release of CCL2 by both the graft and recipient throughout the week following transplantation (n = 28). In a retrospective study of 77 SPK recipients, we found a significant negative association between high donor levels of CCL2 and graft survival. Decreased survival in these patients is related to early posttransplant complications, including a higher incidence of pancreas thrombosis and delayed kidney function. Taken together our data indicate that high CCL2 levels in the donor serum predict both an increase in graft/recipient CCL2 production and poor graft survival. This suggests that the severity of the inflammatory response induced by brain death influences the posttransplant inflammatory response, independent of subsequent ischemia and reperfusion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Brain Death / immunology*
  • Chemokine CCL2 / blood*
  • Chemokine CCL2 / immunology
  • Delayed Graft Function
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 1 / surgery
  • Diabetic Nephropathies / etiology
  • Diabetic Nephropathies / surgery
  • Female
  • Graft Survival / immunology*
  • Humans
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / surgery
  • Kidney Transplantation / immunology*
  • Male
  • Pancreas Transplantation / immunology*
  • Predictive Value of Tests
  • Retrospective Studies
  • Tissue Donors
  • Transplantation Tolerance

Substances

  • Chemokine CCL2

Grants and funding